Amyloid Pathology and Protein Kinase C (PKC): Possible Therapeutics Effects of PKC Activators
-
- Olariu Ana
- Unit on Neuroplasticity, National Institute of Mental Health, National Institutes of Health
-
- Yamada Kiyofumi
- Laboratory of Neuropharmacology, Division of Life Sciences, Kanazawa University Graduate School of Natural Science and Technology
-
- Nabeshima Toshitaka
- Department of Neuropshychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine
この論文をさがす
説明
Amyloid β-protein (Aβ) is one of the most studied peptides in human neurodegenerative disorders. Although much has been learned about the biochemistry of this peptide, fundamental questions such as when and how the Aβ becomes pathologic remain unanswered. In this article we review the recent findings on the biology and pathology of Aβ and the role protein kinase C (PKC) plays in these processes. The potential neuroprotective role of PKC and the possible therapeutic effects of PKC activators in Alzheimer’s disease (AD) will be discussed. Briefly, comments will be also addressed on the role of PKC in cell death and neurogenesis in AD.<br>
収録刊行物
-
- Journal of Pharmacological Sciences
-
Journal of Pharmacological Sciences 97 (1), 1-5, 2005
公益社団法人 日本薬理学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001205176167040
-
- NII論文ID
- 10025724874
-
- NII書誌ID
- AA11806667
-
- ISSN
- 13478648
- 13478613
-
- NDL書誌ID
- 7228312
-
- PubMed
- 15655301
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可